Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia

Abstract

Background and aims

Thrombocytopenia is a common hematological abnormality observed in patients infected with hepatitis C virus (HCV). The use of eltrombopag has been approved for HCV-associated thrombocytopenia. This is the first study aiming to determine the predictive factors of response to eltrombopag therapy in patients with HCV-associated thrombocytopenia.

Patients and methods

This prospective study was carried out on 130 patients with chronic HCV-associated thrombocytopenia (<50,000×10⁹/L) that precludes the initiation of HCV therapy. Eltrombopag was initiated at a dose of 25 mg once daily; the dose was adjusted with 25 mg increments every 2 weeks to achieve the target platelet count. The primary end point was to achieve stable target platelet count (50,000–100,000×10⁹/L) required to initiate antiviral therapy.

Results

Treatment response was achieved in 111 (85.38%) patients. This prospective study showed that megakaryocyte hypoplasia or aplasia and splenectomy were independent risk factors for eltrombopag nonresponse in chronic HCV-associated thrombocytopenic patients.

Conclusion

Eltrombopag is safe and effective for patients with HCV-associated thrombocytopenia. Bone marrow examination should be considered before initiating treatment with eltrombopag in chronic HCV-associated thrombocytopenic patients, especially in patients with splenectomy.

Keywords:

• HCV
• therapy
• thrombocytopenia
• predictors
• splenectomy
• direct-acting antivirals
• DAAs

Disclosure

The authors report no conflicts of interest in this work.